First commercial patient treated with Morphic Medical’s RESET device

Morphic Medical has announced that the first commercial patient has been treated with RESET, the company’s therapy designed to target the underlying cause of obesity and type 2 diabetes. The procedure was performed on 19 September at King’s College Hospital NHS Foundation Trust in London by Professor Bu’Hussain Hayee, the Trust’s Clinical Director for Liver, Endoscopy and Gastroenterology. 

RESET device

“RESET represents an important new option for people living with obesity and type 2 diabetes. It’s a minimally invasive procedure that can be done in 30 minutes, with patients going home the same day, and no alteration to anatomy,” said Professor Hayee. “We also know that the benefits last well beyond the removal of the device. King’s has a distinguished history of care for patients with diabetes and being able to perform the first commercial RESET procedure here in the UK is a proud milestone. I look forward to offering this exciting therapy to more patients.”

It marks the first time RESET has been used outside of a clinical trial and provided as a standard treatment. The procedure, which takes under 30 minutes to perform, was completed successfully and without complication.

Morphic’s RESET treatment is a first-of-its-kind thin sleeve that lines the upper part of the intestine for up to nine months. It helps patients lose weight and improve blood sugar control by changing how food is absorbed and how the gut signals hunger to the body. Unlike surgery, RESET is put in and taken out with a simple endoscopy procedure, and is fully reversible. Over one in five adults across Europe are living with obesity, with the figure rising to one in four in the UK. In addition, diabetes costs the NHS almost £14 billion a year. 

Recently-published data from the world’s largest registry of RESET patients - comprising real-world outcomes in 1,298 patients across 37 centres in 12 countries, including NHS hospitals in Birmingham, London, Southampton, Manchester and Glasgow - confirmed that RESET delivers substantial and durable benefits:

• Patients lost an average of 18.9% of their total body weight

• Blood sugar levels – as measured by HbA1c, the standard test for long-term glucose control – fell by 1.3 percentage points, with the greatest improvements seen in patients starting at higher levels

• Benefits were durable, with 77% of patients maintaining improvement three years after RESET was removed

The new research-driven, nine-month treatment approach delivers all of the benefits of weight loss and reduction in blood sugar, with fewer complications than the 12 month approach

RESET was recently commercially registered for sale by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), completing an important legal requirement for UK sales. The MHRA registration followed July’s CE (Conformité Européenne) Mark designation, which ensures RESET has met all European Commission safety, health and environmental protection requirements. Morphic Medical has begun offering RESET in Germany, with plans to expand across the European Union and other countries recognising CE certification.

“Treating our first commercial patient with RESET is a defining moment for Morphic. It shows that what began as pioneering clinical research is now becoming a reality in everyday medical practice. RESET delivers substantial, durable improvements in both weight and blood sugar control, and does so through a safe, minimally invasive and fully reversible procedure that takes under thirty minutes to perform,” said Mike Gutteridge, President & Chief Executive Officer of Morphic Medical. “With CE Mark approval, MHRA registration and now the first UK patient treated, we are moving quickly to bring RESET to the people and health systems that need it most. Obesity and type 2 diabetes are among the greatest healthcare challenges of our time, costing billions each year and reducing quality of life for millions of people. RESET offers a proven alternative to lifelong medication or invasive surgery – one that can make a lasting difference to patients and relieve the pressure on overstretched healthcare budgets.”